Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Liver Neoplasms 2Liposarcoma 2Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cervical Cancer Metastatic × toripalimab × Clear all
NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡